Clinical Trials Browser

Recruiting × INDUSTRY × osimertinib × Clear all

NCT06618287 2026-03-17

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT06417814 2026-03-02

TROPION-Lung15

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05647122 2026-02-20

EGRET

Phase 1 Recruiting

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase 3 Recruiting

NSCLC Patients With Brain Metastasis

NCT07005102 2026-01-23

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Neoplasms

NCT04486833 2026-01-21

Acclaim-1

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07315113 2026-01-02

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07079475 2025-12-24

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06670196 2025-12-05

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07229729 2025-12-01

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07206498 2025-11-28

WAYWIN103

Phase 1/2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06350097 2025-11-17

TROPION-Lung14

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04665206 2025-10-28

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasmThoracic

Mesothelioma

NCT06574347 2025-05-21

KYLIN-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06498986 2025-05-07

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06895928 2025-04-22

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06829459 2025-04-08

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05785741 2025-03-05

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05261399 2025-01-10

SAFFRON

Phase 3 Recruiting

Carcinoma, Neoplasm Metastasis

NCT06735391 2024-12-16

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Phase 3 Recruiting

Locally Advanced or Metastatic Non-squamous NSCLC

NCT05948813 2024-11-21

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Phase 2 Recruiting

Brain Neoplasms

NCT05382728 2024-01-30

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Phase 3 Recruiting

NSCLC